Naphthalene

Naphthalene

SCHEMBL1154787

C.CO.c1ccc2ccccc2c1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 9/20 0.67
ALOX12 P18054 1/20 0.67
CYP1A2 P05177 5/20 0.45
TDP1 Q9NUW8 2/20 0.45
UGT2B7 P16662 1/20 0.42
ALDH1A1 P00352 4/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CYP3A4 P08684 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Naphthalene SCHEMBL28400557 0.96 CYP2A6 (0.73) CYP2A6ALOX12CYP1A2TDP1UGT2B7
Naphthalene SCHEMBL119524 0.96 CYP2A6 (0.73) CYP2A6ALOX12CYP1A2TDP1UGT2B7
Naphthalene SCHEMBL28184754 0.96 CYP2A6 (0.73) CYP2A6ALOX12CYP1A2TDP1UGT2B7
Naphthalene SCHEMBL27338517 0.92 CYP2A6 (0.67) CYP2A6ALOX12CYP1A2TDP1UGT2B7
Naphthalene SCHEMBL28081404 0.87 CYP2A6 (0.89) CYP2A6ALOX12CYP1A2TDP1ALDH1A1
Naphthalene SCHEMBL16097339 0.87 CYP2A6 (0.89) CYP2A6ALOX12CYP1A2TDP1ALDH1A1
Naphthalene SCHEMBL49569 0.87 CYP2A6 (0.89) CYP2A6ALOX12CYP1A2TDP1ALDH1A1
Naphthalene SCHEMBL11063170 0.87 CYP2A6 (0.89) CYP2A6ALOX12CYP1A2TDP1ALDH1A1
Naphthalene SCHEMBL28051541 0.85 CYP2A6 (0.57) CYP2A6ALOX12CYP1A2TDP1UGT2B7
Naphthalene SCHEMBL27806576 0.83 CYP2A6 (0.67) CYP2A6ALOX12CYP1A2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3121176-A1 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY Families of Spinal Muscular Atrophy (US) 2017-01-25 EP disclosed
EP-1765810-B1 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2016-08-17 EP disclosed
EP-2514748-B1 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2016-08-10 EP disclosed
US-20160152577-A1 2,4-Diaminoquinazolines for Spinal Muscular Atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2016-06-02 US disclosed
US-9067897-B2 2,4-Diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2015-06-30 US disclosed
CN-101851176-B Organic metal iridium catalyst with nitrone ligand JIANGSU SINOCOMPOUND CATALYST CO LTD 2013-07-03 CN disclosed
EP-2514748-A1 2,4-diaminoquinazolines for spinal muscular atrophy Families of Spinal Muscular Atrophy (US) 2012-10-24 EP disclosed
US-20110112118-A1 2,4-Diaminoquinazolines for Spinal Muscular Atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-05-12 US disclosed
US-7888366-B2 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-02-15 US disclosed
CN-101851176-A Novel nitrone ligand, organic metal iridium catalyst and preparation method and application thereof SUZHOU SINOCOMPOUND TECHNOLOGY CO LTD 2010-10-06 CN disclosed
EP-1765810-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY Decode Chemistry, Inc. (US) 2007-03-28 EP disclosed
WO-2005123724-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2005-12-29 WO disclosed
US-20050288314-A1 2,4-diaminoquinazolines for spinal muscular atrophy DECODE CHEMISTRY, INC. (US) 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112118-A1 2,4-Diaminoquinazolines for Spinal Muscular Atrophy SMN1; SMN2, MUSK, MYO3B CYP2A6 3432/4885ALOX12 4738/4885CYP1A2 3706/4885
US-20160152577-A1 2,4-Diaminoquinazolines for Spinal Muscular Atrophy SMN1; SMN2, MUSK, MYO3B CYP2A6 3432/4885ALOX12 4738/4885CYP1A2 3706/4885
US-20050288314-A1 2,4-diaminoquinazolines for spinal muscular atrophy SMN1; SMN2, MUSK, MYO3B CYP2A6 3432/4885ALOX12 4738/4885CYP1A2 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.